The bill is signed into law by President Joe Biden as a part of the 2023 omnibus package.

The Lymphedema Treatment Act passed the Senate as a part of the large year-end Fiscal Year 2023 Omnibus budget package.

The bill passed the House by a vote of 402-13.

A briefing for the Lymphedema Treatment Act was held to update congressional staff progress advancing the bill, and to urge their bosses to support the bill when it comes before them for a vote. The video can be viewed at https://vimeo.com/766638230.

Congresswoman Schakwosky (lead) and Congressman Carter (co-lead), as well as the Health Aides for Senators Cantwell (lead) and Grassley (co-lead) all spoke, followed by panelists from the Oncology Nursing Society, Susan G. Komen, and the Lymphedema Advocacy Group, who explained the importance of this bill to the cancer community and to patients with lymphedema from other causes.

The Lymphedema Advocacy Group has an advocacy toolkit for the Lymphedema Treatment Act related information related to Breast Cancer Awareness month (October). Breast Cancer is the leading cause of lymphedema in the United States.

The Lymphedema Treatment Act received a Congressional Budget Office (CBO) score, which is often a critical step in moving a bill forward.

The bill was placed on the House Consensus calendar.

Avalere Health completed a savings analysis showing that enactment of the Lymphedema Treatment Act (S.1315/H.R.3630) will save the Medicare program a substantial amount - $1.3 to $1.5 billion during the first 10 years. See the analysis here, or in one page form here.

A letter is sent to Reps. Schakowsky, Carter, Blumenauer and Kelly by the Lymphedema Advocacy Group with AACI signed on thanking the members for leading the introduction of the bill in the House.

Re-introduced for the 117th Congress in the House.

A letter to Senators Chuck Grassley (R-IA) and Maria Cantwell (D-WA) is sent by the Lymphedema Advocacy Group with AACI signed on.

Re-introduced for the 117th Congress by Senators Cantwell (D-WA) and Grassley (R-IA). House bill expected to be re-introduced soon.

Roll Call publishes an opinion piece about the importance of passing this legislation by Rep. Buddy Carter (R-GA). The piece notes that "...The legislation currently has tremendous bipartisan backing, with over 380 House and 70 Senate co-sponsors, making it the most supported health care bill in Congress by a large margin."

The Lymphedema Advocacy Group released an infographic urging passage of this bill as a response to the COVID-19 pandemic and also noting that it is currently the most widely co-sponsored bill in Congress.

A Roll Call article discusses why some widely popular bipartisan bills still don't make over the finish line and chronicles the advocacy efforts of the Lymphedema Advocacy Group on this bill.

It is unclear whether the Senate will take up the H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act that includes the Lymphedema Treatment provisions.

Passed/agreed to in House as a part of the larger drug pricing reform bill by the US House of Representatives, H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act: On passage Passed by the Yeas and Nays: 230 - 192. It is unclear that the Senate will take up the H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act that includes the Lymphedema Treatment provisions.

The Association of American Cancer Institutes (AACI) officially signs onto the Lymphedema Advocacy Group's letter in support of H.R.1948/S. 518 Lymphedema Treatment Act